PolymarketVerifica disponibilitàSenza KYCDati di risoluzione verificatiBen calibratoProbabilità implicita attuale
December 31, 67%In testa tra 3 esiti
December 31, 67%Qualità del mercato
63 / 100
Qualità mediaVolume 24h
276 €
Liquidità
19,2K €
Liquidità mediaSpread
1.0 pt
Spread strettoCommenti
0
Dati di mercato
Aggiornato 18 minuti fa
19 ago 26, 17:49 UTC1 gen 28, 04:59 UTC
Trend
Condizioni della piattaforma
Fonte: Polymarket
Queste condizioni sono informative; il trading simulato di CoinRithm segue regole proprie.
- Ordine minimo (quote):
- 5
- Incremento di prezzo:
- 1 punti percentuali
- Commissioni:
- Sì
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
Is Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsSkin cancer vaccine BLA submitted by which date?
PolymarketWill the Russian cancer vaccine work?
Manifold MarketsFDA approves Retatrutide this year?
PolymarketFDA approves YCT-529 male birth control pill before 2035?
Manifold MarketsRegole
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- Differences in neoantigen composition between patients will not affect resolution.
- Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above.
- Approval as part of a combination regimen will qualify.
